Keating Financial Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Keating Financial Advisory Services's NBIX Position: Q2 2026 in Review
Keating Financial Advisory Services increased its Neurocrine Biosciences (NBIX) stake by 34% in Q2 2026, buying an estimated $3.12K and bringing the position to 82 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1126.
Keating Financial Advisory Services first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Keating Financial Advisory Services held 82 shares of Neurocrine Biosciences worth $13.8K as of Q2 2026.
- Keating Financial Advisory Services bought 21 Neurocrine Biosciences shares in Q2 2026, an estimated $3.12K.
- Neurocrine Biosciences made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1126 holding.
- Keating Financial Advisory Services first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
- 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.